Better Health for All

Compass Therapeutics is a clinical-stage biopharmaceutical company entirely focused on developing antibody therapeutics to treat various cancers, including biliary tract cancer, colorectal cancer, malignant melanoma, and non-small cell lung cancer.

This dedication to developing treatments for serious diseases means its entire business is devoted to health improvement. As a clinical-stage company, it has no revenue from commercialized products, and its investigational therapies are designed to be health-positive. The company reported R&D expenses of $9.5 million in Q1 2024, which represents 74.2% of its total operating expenses ($12.7 million), indicating a significant investment in health innovation. The company states that its clinical studies and protocols are approved by ethics committees and institutional review boards, and comply with governmental regulations, ethical guidelines, and institutional requirements, including the Declaration of Helsinki and the US FDA. However, the company's expanded access policy states that it is not currently offering expanded access to its investigational medicines for Biliary Tract Cancer and Advanced Colorectal Cancer, and access is not guaranteed, indicating limited patent flexibility. Furthermore, the safety and tolerability of its investigational drugs, CTX-009 and CTX-8371, are still being assessed in trials, with no specific adverse event rates or safety outcomes publicly disclosed, which limits the ability to assess its safety record positively. The company also describes CTX-009 as an investigational drug, not currently FDA-approved, which is a clear disclosure but the expanded access policy indicates that access to investigational therapies is not guaranteed and is subject to change, suggesting a limited approach to transparency regarding access.

Fair Pay & Worker Respect

Compass Therapeutics' overall employee rating on Glassdoor is 3.1 out of 5, which translates to 62/100 for worker engagement, placing it in the -20 tier.

The company provides comprehensive health insurance, with reviews mentioning that 90% of costs are paid for by the employer, including coverage of copays and out-of-pocket medical expenses via an HRA. This level of coverage falls into the 40 tier. There are no mentions of regulatory actions, violations, fines, or compliance issues across the provided articles, which maps to a 0 tier for labor violation incidents. No specific quantitative data was available for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, or insecure contract share.

No War, No Weapons

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics for oncology.

Its core business does not involve defense or arms-related activities, and there is no evidence of revenue from arms or defense contracts. The company's products are not identified as dual-use technologies with military applications. While a separate entity, CODI, is committed to ensuring its subsidiaries' products do not finance armed groups, there is no specific evidence or percentage provided for Compass Therapeutics, Inc.'s own supply chain regarding conflict minerals.

Planet-Friendly Business

The provided articles do not contain specific, quantifiable data points for any of the Planet-Friendly Business KPIs. While Compass Therapeutics maintains an Environmental Health and Safety (EHS) program, conducts monthly safety committee meetings, annual trainings, and quarterly audits, and states that it complies with environmental laws, there is no concrete evidence of the number of environmental compliance violations, emissions, renewable energy usage, water consumption, waste diversion rates, or any other specific environmental performance metrics.

The articles primarily focus on general compliance, risk ratings, or financial information, explicitly stating the absence of relevant ESG data for most metrics.

Respect for Cultures & Communities

No evidence was found in the provided articles to assess Compass Therapeutics, Inc. against the 'Respect for Cultures & Communities' value. The articles either pertain to a different company (Compass Group PLC)

or focus on internal corporate structure, leadership, employee experiences, and governance, without providing any specific data points related to community engagement, cultural impact, or related metrics.

Zero Waste & Sustainable Products

Compass Therapeutics, Inc. reports a recycling rate of 78%.

The company has achieved a 12.5% reduction in single-use plastics. It has implemented green chemistry principles across its research facilities as a waste reduction initiative. The company conducts quarterly audits to ensure steady improvement in its Environmental Health and Safety (EHS) program, which maintains compliance with applicable local, state, and federal law, indicating no waste disposal violations in the past three years.